Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311948838> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4311948838 endingPage "109" @default.
- W4311948838 startingPage "103" @default.
- W4311948838 abstract "Currently, eight natural serotypes of botulinum neurotoxin (BNT-A-G, -X) are known. The mechanism of action of all BNT serotypes is presynaptic blockade of SNARE transport proteins (Soluble N-ethylmaleimide-sensitive factor [NSF] Attachment Protein Receptor), as a result of which the release of acetylcholine into the synaptic cleft is disrupted and neuromuscular transmission is blocked. Each botulinum toxin serotype selectively binds to its own presynaptic membrane receptor and causes cleavage of its own SNARE protein. These differences determine the neuronal specificity and activity of botulinum toxins, which leads to their unique pharmacological properties, such as activity, duration of action, and time to onset of action. In the international clinical practice, only two BNT serotypes (A and B) are allowed to be used, however, in recent years, a large number of studies on the efficacy and safety of other BNT serotypes (E, C, F) have been carried out, and technologies for changing their natural properties have been developed. One of the indications for the use of botulinum therapy in neurology is the correction of post-stroke spasticity. Currently, BNT-A is used for this purpose, clinical improvement after its injection occurs after 2 weeks, the therapeutic effect persists for 3 months, and then the symptoms of spasticity increase again, which worsens the patient's quality of life and reduces the possibility of medical rehabilitation. The use of fast-acting recombinant botulinum toxins for this purpose could help overcome this disadvantage of BNT-A therapy. Currently the LANTIMA study, supported by IPSEN company, is going on to evaluate the safety profile and level of efficacy of modified recombinant botulinum toxin type AB in the treatment of upper limb spasticity in adults." @default.
- W4311948838 created "2023-01-03" @default.
- W4311948838 creator A5028714244 @default.
- W4311948838 creator A5043968768 @default.
- W4311948838 date "2022-12-19" @default.
- W4311948838 modified "2023-10-14" @default.
- W4311948838 title "Recombinant botulinum toxin as a new stage in the development of botulinum toxin therapy. Possibilities and perspectives of use in neurological practice" @default.
- W4311948838 cites W1057607901 @default.
- W4311948838 cites W1965137822 @default.
- W4311948838 cites W1981764249 @default.
- W4311948838 cites W1984235249 @default.
- W4311948838 cites W2003607836 @default.
- W4311948838 cites W2010455127 @default.
- W4311948838 cites W2077168582 @default.
- W4311948838 cites W2078541439 @default.
- W4311948838 cites W2089927506 @default.
- W4311948838 cites W2090106870 @default.
- W4311948838 cites W2093235237 @default.
- W4311948838 cites W2101211619 @default.
- W4311948838 cites W2122977798 @default.
- W4311948838 cites W2162232417 @default.
- W4311948838 cites W2180791972 @default.
- W4311948838 cites W2228148711 @default.
- W4311948838 cites W2253779929 @default.
- W4311948838 cites W2570737269 @default.
- W4311948838 cites W2578933961 @default.
- W4311948838 cites W2598060151 @default.
- W4311948838 cites W2638512329 @default.
- W4311948838 cites W2682693068 @default.
- W4311948838 cites W2793367962 @default.
- W4311948838 cites W2804327673 @default.
- W4311948838 cites W2806839281 @default.
- W4311948838 cites W2811272786 @default.
- W4311948838 cites W2902250414 @default.
- W4311948838 cites W2902717520 @default.
- W4311948838 cites W2947386092 @default.
- W4311948838 cites W2980280693 @default.
- W4311948838 cites W3010789328 @default.
- W4311948838 cites W3023001063 @default.
- W4311948838 cites W3117002056 @default.
- W4311948838 cites W3205165411 @default.
- W4311948838 cites W3216406925 @default.
- W4311948838 doi "https://doi.org/10.14412/2074-2711-2022-6-103-109" @default.
- W4311948838 hasPublicationYear "2022" @default.
- W4311948838 type Work @default.
- W4311948838 citedByCount "0" @default.
- W4311948838 crossrefType "journal-article" @default.
- W4311948838 hasAuthorship W4311948838A5028714244 @default.
- W4311948838 hasAuthorship W4311948838A5043968768 @default.
- W4311948838 hasBestOaLocation W43119488381 @default.
- W4311948838 hasConcept C126322002 @default.
- W4311948838 hasConcept C169760540 @default.
- W4311948838 hasConcept C2777478456 @default.
- W4311948838 hasConcept C2779012798 @default.
- W4311948838 hasConcept C42219234 @default.
- W4311948838 hasConcept C71924100 @default.
- W4311948838 hasConcept C86803240 @default.
- W4311948838 hasConcept C98274493 @default.
- W4311948838 hasConceptScore W4311948838C126322002 @default.
- W4311948838 hasConceptScore W4311948838C169760540 @default.
- W4311948838 hasConceptScore W4311948838C2777478456 @default.
- W4311948838 hasConceptScore W4311948838C2779012798 @default.
- W4311948838 hasConceptScore W4311948838C42219234 @default.
- W4311948838 hasConceptScore W4311948838C71924100 @default.
- W4311948838 hasConceptScore W4311948838C86803240 @default.
- W4311948838 hasConceptScore W4311948838C98274493 @default.
- W4311948838 hasIssue "6" @default.
- W4311948838 hasLocation W43119488381 @default.
- W4311948838 hasOpenAccess W4311948838 @default.
- W4311948838 hasPrimaryLocation W43119488381 @default.
- W4311948838 hasRelatedWork W167718453 @default.
- W4311948838 hasRelatedWork W1969027527 @default.
- W4311948838 hasRelatedWork W1981158466 @default.
- W4311948838 hasRelatedWork W2005762025 @default.
- W4311948838 hasRelatedWork W2021069295 @default.
- W4311948838 hasRelatedWork W2172297050 @default.
- W4311948838 hasRelatedWork W2329511336 @default.
- W4311948838 hasRelatedWork W2409205401 @default.
- W4311948838 hasRelatedWork W3022466741 @default.
- W4311948838 hasRelatedWork W4312703431 @default.
- W4311948838 hasVolume "14" @default.
- W4311948838 isParatext "false" @default.
- W4311948838 isRetracted "false" @default.
- W4311948838 workType "article" @default.